IP Library Granted Patent US 9,180,189
Granted Patent B2
US 9,180,189 · App. 11/305,254 · Granted Nov 10, 2015

Treating a mammal with a formulation comprising an antibody which binds IgE

Inventors: James Andya (Millbrae, CA); Chung C. Hsu (Los Altos Hills, CA); Steven J. Shire (Belmont, CA); Sylvia Sau-Yan Wu (San Francisco, CA)
Assignee: GENENTECH, INC.
A61K39/39591A61K38/16C07K16/4291A61K2039/505C07K2317/24Y10S435/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,180,189
App. No.
11/305,254
Granted
Nov 10, 2015
Kind
B2
Abstract

A method of treating a mammal with a formulation comprising an antibody which binds IgE as described.

Claims (4)

1. A method for treating a human comprising administering by subcutaneous injection a therapeutically effective amount of a stable reconstituted formulation to the human in order to treat an IgE-mediated allergic disease in the human, wherein the reconstituted formulation comprises an antibody which binds IgE, in a concentration from 80 mg/mL to 400 mg/mL and has been prepared by reconstituting a lyophilized mixture of the antibody and a lyoprotectant in a diluent, wherein the molar ratio of lyoprotectant:antibody is 100-1000 mole lyoprotectant:1 mole of antibody, wherein the antibody concentration in the reconstituted formulation is 2-40 times greater than the antibody concentration in the mixture before lyophilization, and wherein the reconstituted formulation is administered in an injection volume of 1.5 mL or less.

2. The method of claim 1 wherein about 1-15 mg/kg of the antibody is administered to the human.

3. The method of claim 1 , wherein the antibody concentration of the reconstituted formulation is 3-10 times greater than the antibody concentration in the mixture before lyophilization.

4. The method of claim 3 , wherein the antibody concentration of the reconstituted formulation is 3-6 times greater than the antibody concentration in the mixture before lyophilization.

Continuity (4)
Continuation 09705457 · Nov 2, 2000
Division 08615369 · Mar 14, 1996
Provisional Application 60029182 · Jul 27, 1995
Related Publication 20060099201A1 · May 11, 2006